Lurbinectedin Combo FDA Approved for Extensive Small Cell Lung Cancer
- * Disease: small cell lung cancer (SCLC) is an aggressive and frequently enough fatal disease.
Here’s a breakdown of the key details from the provided text:
* Disease: small cell lung cancer (SCLC) is an aggressive and frequently enough fatal disease. Only 20% of patients survive longer than 2 years after diagnosis, as most are diagnosed at an advanced (extensive-stage) point.
* New Treatment: A combination therapy of lurbinectedin with atezolizumab (or atezolizumab and hyaluronidase-tqjs) has been approved by the FDA.
* Clinical Trial (IMforte): The IMforte trial showed encouraging results, potentially offering a practice-changing option to improve survival for SCLC patients.
* Source of Information:
* FDA Approval: Announced October 2, 2025 (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-extensive)
* Published study: Paz-Ares et al. published the IMforte trial results in The Lancet in 2025 (DOI: 10.1016/S0140-6736(25)01011-6).
* Expert Opinion: Dr. Luis Paz-Ares, the principal investigator of IMforte, believes the results are very encouraging and could significantly improve outcomes for patients with this difficult-to-treat cancer.